As of 2026, neurotoxin exposure treatment has entered a new phase characterized by the use of retrograde transport inhibitors. These novel drugs are designed to prevent the botulinum toxin from moving along the axon, effectively containing the nerve damage to the initial site of exposure. This advancement is particularly crucial for patients suffering from wound-based botulinum toxin poisoning,...